Home
News
Create
Screeners
Insights
Auro Laboratories
250.
10
-5.90
(-2.30%)
Market Cap
₹155.92 Cr
PE Ratio
86.78
Industry
Healthcare
Buy
Sell
Company Performance:
1D
-2.30%
1M
-5.64%
6M
+16.33%
1Y
-1.34%
5Y
+150.60%
View Company Insights
Latest news about Auro Laboratories
Auro Laboratories Receives Credit Rating Assignment from Acuite Ratings for Rs.79.80 Crore Bank Facilities
9 days ago
Auro Laboratories Limited received credit ratings from Acuite Ratings & Research Limited for Rs.79.80 crore bank facilities, with ACUITE BB+ stable for Rs.64.20 crore long-term facilities and ACUITE A4+ for Rs.15.60 crore short-term facilities. The ratings reflect the company's extensive promoter experience and three-decade operational track record, while considering constraints from modest operations scale and intensive working capital requirements. The pharmaceutical API manufacturer recently completed capacity expansion increasing manufacturing from 1,260 MT to 2,100 MT annually, though revenue declined to Rs.19.40 crore in FY2025 from Rs.53.64 crore in FY2024 due to the expansion period.
Auro Laboratories Files Quarterly Dematerialization Certificate for Q4FY26
9 days ago
Auro Laboratories Reports Strong Q3FY26 Results with 206% Revenue Growth
Feb 05, 2026
Auro Laboratories Limited Schedules Board Meeting on February 05, 2026 for Q3FY26 Financial Results
Jan 28, 2026
Auro Laboratories Secures WHO-GMP Certification for API Manufacturing Facility
Nov 13, 2025
More news about Auro Laboratories
13
Nov 25
Auro Laboratories Reports Quarterly Loss of Rs 71.58 Lakhs
Auro Laboratories Limited reported a net loss of Rs 71.58 lakhs for Q2 FY2026, up from Rs 10.55 lakhs loss in Q1. Revenue from operations increased to Rs 883.67 lakhs from Rs 217.42 lakhs in the previous quarter. Total income rose to Rs 981.25 lakhs, but expenses also increased significantly to Rs 809.27 lakhs. The company's total assets stood at Rs 11,077.34 lakhs with total equity of Rs 4,357.84 lakhs. On a positive note, Auro Laboratories received a WHO-GMP Certificate for its API manufacturing facility, valid until September 30, 2028.
23
Aug 25
Auro Laboratories Announces Key Management Changes and Auditor Appointments
Auro Laboratories Ltd has made significant changes in its management and auditing structure. The company appointed M/s B.L. Dasharda & Associates as new Statutory Auditors for five years, replacing M/s Kothari Jain & Associates. Mrs. Kavita Vijayakant Sharma was re-appointed as Non-Executive Independent Director for a second five-year term. Ms. Padma Tapariya was named new Company Secretary and Compliance Officer. M/s GMJ & Associates were appointed as Secretarial Auditors for five years. The company's 36th Annual General Meeting is scheduled for September 25, 2025, to be held via video conferencing.
Auro Laboratories
250.
10
-
5.
90
(-
2.
30
%)
1 Year Returns:
-1.34%
Industry Peers
Sun Pharmaceutical
1,620.20
(-
3.
57
%)
Divis Laboratories
6,371.00
(-
0.
12
%)
Torrent Pharmaceuticals
4,134.00
(-
0.
32
%)
Dr Reddys Laboratories
1,322.60
(-
0.
63
%)
Cipla
1,297.40
(-
0.
65
%)
Lupin
2,281.10
(-
2.
58
%)
Mankind Pharma
2,279.10
(-
0.
60
%)
Zydus Life Science
928.65
(-
1.
87
%)
Aurobindo Pharma
1,416.30
(-
1.
33
%)
Alkem Laboratories
5,447.00
(-
1.
33
%)
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/ Block Deals
Stock Rental via SLBM
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation
IPO